NEW YORK, Jan. 21, 2016 — Centinel Spine, Inc., (Centinel Spine) announces the U.S. Food and Drug Administration (FDA) clearance of ALTOS™, a posterior cervical thoracic stabilization system indicated for use in either the lateral masses of the cervical spine or the pedicles of the cervical-thoracic spine. The first surgical implantation of the ALTOS system was performed by Gery Hsu, MD, CRMC Medical Associates, Coffeyville, KS on January 4, 2016.
“Centinel Spine is dedicated to developing products that address surgical needs, anatomical challenges and surgeon requirements,” said John J. Viscogliosi, Chairman & CEO, Centinel Spine. “We look forward to seeing the successful clinical outcomes and evidence that ALTOS was designed to achieve,” Mr. Viscogliosi continued.
ALTOS is the first FDA cleared posterior cervical thoracic system specifically designed for implantation into either the cervical lateral masses or the cervical-thoracic pedicles. This low profile, stabilization system offers both fully threaded and smooth shank polyaxial screws with 80 degrees of freedom for simple insertion in the most demanding spinal anatomies. The system also provides laminar hooks, connectors, straight and curved rods for customizable constructs that meet each patient’s anatomical needs to provide outstanding clinical outcomes.
Jason E. Garber, MD, FACS, Western Regional Center for Brain & Spine Surgery, Las Vegas, NV, explained, “ALTOS is a comprehensive system that was designed to provide the surgical versatility needed to address posterior cervical spinal pathologies. The low profile system is simple to insert minimizing patient trauma and surgical time. It can also be easily customized to successfully address many patients’ degenerative pathologies.”
In addition to ALTOS, Centinel Spine also develops, manufactures, markets and sells the complete STALIF® product family, which includes STALIF C®, STALIF C-Ti™, MIDLINE II™ and MIDLINE II-Ti™. STALIF C-Ti and MIDLINE II-Ti merge the proven clinical success of STALIF Integrated Interbody technology with Ti-ACTIVE™, a titanium coating engineered with over 15 years of science and experience to produce an optimized, surface topography enabling cellular proliferation.1, 2, 3, 4
“We are proud to deliver the ALTOS system, Ti-ACTIVE technology and STALIF product families to patients around the world,” explained Mr. Viscogliosi. “The ALTOS system exemplifies our commitment to advancing the standard of care in spinal fusion procedures with our clinically proven technologies.”
For more information on Altos PCT, please visit http://altospct.centinelspine.com.
About Centinel Spine, Inc.
Centinel Spine, Inc. is a privately-held spinal device company leading the development and commercialization of the Stand-Alone, No-Profile, Integrated Interbody fusion technologies. For more information on Centinel Spine products and technologies, please visit the Company’s web site at www.centinelspine.com.
The company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica LLC and Surgicraft LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies and continues its corporate mission of becoming the leading anterior column support spine franchise, providing elegantly simple implants and instruments that are tissue-sparing and generating superior clinical outcomes.
Centinel Spine derived its name from the “Sentinel Sign” – the radiographic confirmation of a successful fusion anterior to the interbody device.
For more information, please contact:
Centinel Spine, Inc.
900 Airport Road, Suite 3B
West Chester, PA 19380
- Lebl DR. Mechanical performance of cervical TDRs in vivo. Spine (Phila, PA 1976) 2012 Dec 15; 37(26): 2151-60.
- References on File/Internal Reports; Centinel Spine, Inc. LBL 073 Rev 1.
- Centinel Spine Report VAL-2014-009.
- Centinel Spine Report CD12-03-07-038.
LBL 201 R01